Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 5, 2020 21:50 UTC |
Ahlberg Gregory ASenior Vice President
|
GrantCommon shares without par value | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010243 · edgar.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:48 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 72 | $108.83 | $7,835.76 |
DisclosureSEC source: 0001179110-20-010065 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,116 Underlying: Common Shares · 72 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:49 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 289 | $108.83 | $31,451.87 |
DisclosureSEC source: 0001179110-20-010066 · edgar.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,743 Underlying: Common Shares · 289 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC |
Wainer Andrea FExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · derivative · entry 3 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 30,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC |
Wainer Andrea FExecutive Vice President
|
SaleCommon shares without par value | 30,000 | $107.01 | $3,210,360.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · nonDerivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,080 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 21:50 UTC |
Wainer Andrea FExecutive Vice President
|
Exercise / conversionCommon shares without par value | 30,000 | $38.40 | $1,152,000.00 |
DisclosureSEC source: 0001179110-20-010067 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:06 UTC |
Wainer Andrea FExecutive Vice President
|
SaleCommon shares without par value | 3,650 | $102.47 | $374,031.20 |
DisclosureSEC source: 0001179110-20-009962 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,080 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.47 to $102.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 22:14 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
SaleCommon shares without par value | 2,500 | $105.28 | $263,200.00 |
DisclosureSEC source: 0001179110-20-009786 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,267 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 21:52 UTC |
BIRD ROGERSenior Vice President
|
SaleCommon shares without par value | 6,290 | $108.73 | $683,929.31 |
DisclosureSEC source: 0001179110-20-009564 · edgar.xml · nonDerivative · entry 1 BIRD ROGER · CIK 0001635313 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,630 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.54 to $108.86, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 39,953 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 7 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 39,953 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 20,133 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 6 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 20,133 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 12,012 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · derivative · entry 5 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,709 Underlying: Common shares · 12,012 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Tax withholdingCommon shares without par value | 47,772 | $109.47 | $5,229,600.84 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 4 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,003 Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionCommon shares without par value | 39,953 | $44.40 | $1,773,913.20 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 3 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionCommon shares without par value | 20,133 | $38.40 | $773,107.20 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:33 UTC |
Ginascol John FExecutive Vice President
|
Exercise / conversionCommon shares without par value | 12,012 | $47.00 | $564,564.00 |
DisclosureSEC source: 0001179110-20-009571 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 52,300 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 52,300 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC |
CAPEK JOHN MExecutive Vice President
|
SaleCommon shares without par value | 52,300 | $111.86 | $5,850,278.00 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,800 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:27 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionCommon shares without par value | 52,300 | $27.03 | $1,413,857.28 |
DisclosureSEC source: 0001179110-20-009446 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 42,479 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 42,479 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
SaleCommon shares without par value | 42,479 | $111.86 | $4,751,700.94 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,433 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Exercise / conversionCommon shares without par value | 42,479 | $47.00 | $1,996,513.00 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2020 Filed Aug 4, 2020 21:15 UTC |
Moreland Mary KExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,244 | $100.64 | $125,196.16 |
DisclosureSEC source: 0001179110-20-008703 · edgar.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,887 Read SEC document |
| July 24, 2020 Filed Jul 28, 2020 21:16 UTC |
BRYNELSEN CHARLESSenior Vice President
|
Tax withholdingCommon shares without par value | 1,650 | $100.82 | $166,353.00 |
DisclosureSEC source: 0001179110-20-008528 · edgar.xml · nonDerivative · entry 1 BRYNELSEN CHARLES · CIK 0001712459 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,810 Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:06 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionOption (right to buy) · Derivative | 3,739 | $0.00 Strike: $25.05 | $0.00 |
DisclosureSEC source: 0001179110-20-008493 · edgar.xml · derivative · entry 3 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,739 shares Expires 2021-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:06 UTC |
NOVAKOVIC PHEBE NDirector
|
SaleCommon shares without par value | 933 | $100.78 | $94,025.87 |
DisclosureSEC source: 0001179110-20-008493 · edgar.xml · nonDerivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,113 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.7601 to $100.781, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 21:06 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionCommon shares without par value | 3,739 | $25.05 | $93,676.53 |
DisclosureSEC source: 0001179110-20-008493 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 21:07 UTC |
AUSTIN ROXANNE SDirector
|
SaleCommon shares without par value | 6,844 | $99.80 | $683,038.04 |
DisclosureSEC source: 0001179110-20-008465 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,043 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.80 to $99.81, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 23,008 | $0.00 Strike: $50.72 | $0.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · derivative · entry 4 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,008 Underlying: Common shares · 23,008 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Tax withholdingCommon shares without par value | 2,437 | $99.08 | $241,457.96 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 3 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,454 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC |
PEDERSON MICHAEL JSenior Vice President
|
SaleCommon shares without par value | 23,008 | $98.00 | $2,254,784.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 2 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,891 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:04 UTC |
PEDERSON MICHAEL JSenior Vice President
|
Exercise / conversionCommon shares without par value | 23,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008462 · edgar.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:05 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,060 | $99.08 | $105,024.80 |
DisclosureSEC source: 0001179110-20-008463 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,433 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:06 UTC |
Wellisch Alejandro DSenior Vice President
|
Tax withholdingCommon shares without par value | 524 | $99.08 | $51,917.92 |
DisclosureSEC source: 0001179110-20-008464 · edgar.xml · nonDerivative · entry 2 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,643 Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:06 UTC |
Wellisch Alejandro DSenior Vice President
|
GrantCommon shares without par value | 1,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-008464 · edgar.xml · nonDerivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,167 F1 · shares: Settlement of performance-based restricted stock units in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 22:17 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 344 | $91.43 | $31,451.92 |
DisclosureSEC source: 0001104659-20-079856 · a4.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,434 Underlying: Common Shares · 344 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 22:17 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 86 | $91.43 | $7,862.98 |
DisclosureSEC source: 0001104659-20-079857 · a4.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,015 Underlying: Common Shares · 86 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:07 UTC |
Earnhardt Lisa DExecutive Vice President
|
SaleCommon shares without par value | 872 | $90.84 | $79,215.97 |
DisclosureSEC source: 0001179110-20-007293 · edgar.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,074 Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 21:07 UTC |
Earnhardt Lisa DExecutive Vice President
|
Tax withholdingCommon shares without par value | 2,855 | $90.27 | $257,720.85 |
DisclosureSEC source: 0001179110-20-007293 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,946 Read SEC document |
| June 04, 2020 Filed Jun 12, 2020 21:06 UTC |
WHITE MILES DDirector · Executive Chairman
|
GiftCommon shares without par value | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007292 · edgar.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,180,943 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:01 UTC |
Wainer Andrea FExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,768 | $92.62 | $163,752.16 |
DisclosureSEC source: 0001179110-20-007034 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,730 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:02 UTC |
Ginascol John FExecutive Vice President
|
Tax withholdingCommon shares without par value | 1,768 | $92.62 | $163,752.16 |
DisclosureSEC source: 0001179110-20-007035 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,677 Read SEC document |
| May 15, 2020 Filed May 22, 2020 21:03 UTC |
Ford Robert BDirector · President and CEO
|
GiftCommon shares without par value | 20,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006504 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 135,243 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| May 15, 2020 Filed May 22, 2020 21:03 UTC |
Ford Robert BDirector · President and CEO
|
GiftCommon shares without par value | 20,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006504 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,625 Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 38,732 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · derivative · entry 6 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,925 Underlying: Common shares · 38,732 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 41,268 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · derivative · entry 5 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 41,268 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC |
LANE ANDREW HExecutive Vice President
|
SaleCommon shares without par value | 80,000 | $92.00 | $7,360,104.00 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 3 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,822 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.02, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionCommon shares without par value | 38,732 | $38.40 | $1,487,308.80 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:02 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionCommon shares without par value | 41,268 | $48.90 | $2,018,005.20 |
DisclosureSEC source: 0001179110-20-005553 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 22:34 UTC |
WOODGRIFT RANDEL WILLIAMSenior Vice President
|
SaleCommon shares without par value | 3,724 | $93.18 | $347,012.37 |
DisclosureSEC source: 0001179110-20-005291 · edgar.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,767 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.17 to $93.274, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.